<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002653</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064187</org_study_id>
    <secondary_id>MRC-LEUK-MYEL-VIII</secondary_id>
    <secondary_id>EU-94031</secondary_id>
    <nct_id>NCT00002653</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma</brief_title>
  <official_title>VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is most effective in treating older patients&#xD;
      with multiple myeloma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy&#xD;
      with or without cyclophosphamide and prednisone in treating older patients with multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of doxorubicin, carmustine, cyclophosphamide, and melphalan (ABCM)&#xD;
           with or without oral cyclophosphamide and prednisone as induction for the first plateau&#xD;
           phase in elderly patients with previously untreated multiple myeloma.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center.&#xD;
&#xD;
      Patients receive doxorubicin IV followed immediately by carmustine IV over 1-2 hours on day 1&#xD;
      and oral melphalan (L-PAM) and oral cyclophosphamide (CTX) on days 22-25 (ABCM). Treatment&#xD;
      continues every 6 weeks for 3 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients whose blood counts recover within 6 weeks after beginning L-PAM and CTX&#xD;
      during course 3 are randomized to 1 of 2 treatment arms. Patients whose blood counts fail to&#xD;
      recover within 6 weeks after beginning L-PAM and CTX during course 3 are assigned to arm II.&#xD;
&#xD;
        -  Arm I: Patients continue ABCM for a maximum of 12 courses in the absence of a plateau&#xD;
           phase after completion of at least 4 courses, disease progression, or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral cyclophosphamide once weekly and oral prednisone every&#xD;
           other day. Treatment continues every 6 weeks in the absence of a plateau phase after&#xD;
           completion of 3 courses of ABCM plus a minimum of 8 weeks on arm II or less than 3&#xD;
           courses of ABCM plus 6 months on arm II, disease progression, or unacceptable toxicity.&#xD;
&#xD;
      Patients on both arms with bone pain or failure to respond to chemotherapy may undergo&#xD;
      minimal radiotherapy. Patients achieving plateau phase may enter the MRC trial of interferon&#xD;
      alfa-2b.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study within&#xD;
      approximately 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 1993</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma, defined by at least 2 of the following conditions:&#xD;
&#xD;
               -  Neoplastic cell infiltrate and/or microplasmacytomas by bone marrow sections or&#xD;
                  smears&#xD;
&#xD;
                    -  Plasma cell infiltrates greater than 20% of marrow nucleated cells or, if&#xD;
                       less than 20%, objective evidence of monoclonality of the plasma cells&#xD;
                       required&#xD;
&#xD;
               -  Paraprotein in blood or urine&#xD;
&#xD;
               -  Definite lytic bone lesions (not osteoporosis)&#xD;
&#xD;
          -  Nonsecretory disease allowed in the presence of 1 of the following conditions:&#xD;
&#xD;
               -  Microplasmacytomas&#xD;
&#xD;
               -  Monoclonal plasmacytosis with immunoglobulin light-chain expression in cytoplasm&#xD;
&#xD;
          -  No equivocal myelomatosis, defined by the following criteria:&#xD;
&#xD;
               -  Minimal or no symptoms attributable to myelomatosis&#xD;
&#xD;
               -  Pretransfusion hemoglobin greater than 10 g/dL&#xD;
&#xD;
               -  Post-hydration creatinine less than 1.47 mg/dL&#xD;
&#xD;
               -  No osteolytic lesions except minimal lesions that do not threaten pathological&#xD;
                  fracture and are not associated with pain&#xD;
&#xD;
               -  Plasma cells less than 30% of marrow nucleated cells and marrow showing normal&#xD;
                  hematopoietic activity&#xD;
&#xD;
               -  Serum beta-2 microglobulin less than 4 mg/L&#xD;
&#xD;
               -  Less than 1 g of free light-chain excretion per 1 g of creatinine&#xD;
&#xD;
               -  No objective factors indicating progressive myelomatosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  65 to 74&#xD;
&#xD;
          -  If under 65, higher priority is given to protocol MRC-LEUK-MYEL-VII unless entry into&#xD;
             this study would be more appropriate&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Neutrophil count at least 1,300/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Ability to tolerate fluid intake of at least 3 L/day beginning at least 2 days before&#xD;
             study entry&#xD;
&#xD;
          -  Afebrile and free of infection&#xD;
&#xD;
          -  No contraindication to therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior or concurrent prednisolone at 30 mg/m2/day or less (or equivalent doses of other&#xD;
             corticosteroids) for relief of fluid-unresponsive hypercalcemia allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior or concurrent minimal local radiotherapy to relieve persistent bone pain or cord&#xD;
             compression allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. T. Drayson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MRC Myelomatosis Trials Office</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRC Myelomatosis Trials Office</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2SZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

